[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 73,519,800
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,629 M
  • EBITDA $ 4,173 M
  • 60-Month Beta 0.24
  • Price/Sales 5.12
  • Price/Cash Flow 16.56
  • Price/Book 2.34

Options Overview Details

View History
  • Implied Volatility 30.36% (-9.23%)
  • Historical Volatility 31.38%
  • IV Percentile 9%
  • IV Rank 18.17%
  • IV High 49.01% on 10/10/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 1) 5.02 (0.68%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 5,213
  • Volume Avg (30-Day) 1,542
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 43,131
  • Open Int (30-Day) 38,367
  • Expected Range 733.33 to 743.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $8.00
  • Number of Estimates 6
  • High Estimate $10.21
  • Low Estimate $5.66
  • Prior Year $10.72
  • Growth Rate Est. (year over year) -25.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
623.89 +18.34%
on 07/01/26
740.00 -0.22%
on 07/30/26
+114.80 (+18.41%)
since 06/30/26
3-Month
591.52 +24.82%
on 06/02/26
740.00 -0.22%
on 07/30/26
+31.28 (+4.42%)
since 04/30/26
52-Week
541.00 +36.48%
on 10/13/25
821.11 -10.08%
on 01/09/26
+183.76 (+33.13%)
since 07/30/25

Most Recent Stories

More News
REGN Deadline Alert: SueWallSt Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026

Important Notice Regarding Alleged Phase III Fianlimab-Libtayo Clinical Trial Risk Misrepresentations. The lawsuit alleges Regeneron investors overpaid while the Company characterized slowing...

REGN : 738.34 (+6.17%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN

NEW YORK , July 30, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such...

REGN : 738.34 (+6.17%)
Regeneron’s (NASDAQ:REGN) Q2 CY2026: Strong Sales

Regeneron’s (NASDAQ:REGN) Q2 CY2026: Strong Sales

REGN : 738.34 (+6.17%)
Regeneron: Q2 Earnings Snapshot

Regeneron: Q2 Earnings Snapshot

REGN : 738.34 (+6.17%)
Regeneron Reports Second Quarter 2026 Financial and Operating Results

Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025 Dupixent ® global net sales (recorded by Sanofi) increased 38% to a new all-time high of $6.0 billion...

REGN : 738.34 (+6.17%)
Regeneron: The Streak Everyone Expects May Finally Require Actual Results

Barchart Research What to Expect from REGN Earnings REGN Generated July 29, 2026 Current Price $695.42 EPS Estimate $$8.00 Consensus Rating Moderate Buy Average Move 5.43% Regeneron: The Streak Everyone...

REGN : 738.34 (+6.17%)
REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman

SAN FRANCISCO , July 29, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN)  faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical...

REGN : 738.34 (+6.17%)
REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron Pharmaceuticals, Inc. Stockholders of Securities Class Action - Contact the Firm

Time-Sensitive: Allegations focus on Regeneron's statements about clinical differentiation in the Phase III Fianlimab-Libtayo Study and the last-minute protocol amendment used to force a trial readout....

REGN : 738.34 (+6.17%)
Regeneron (REGN) To Report Earnings Tomorrow: Here Is What To Expect

Regeneron (REGN) To Report Earnings Tomorrow: Here Is What To Expect

REGN : 738.34 (+6.17%)
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS

SAN FRANCISCO , July 28, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN)  faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical...

REGN : 738.34 (+6.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 798.92
2nd Resistance Point 769.46
1st Resistance Point 753.90
Last Price 738.34
1st Support Level 708.88
2nd Support Level 679.42
3rd Support Level 663.86

See More

52-Week High 821.11
Last Price 738.34
Fibonacci 61.8% 714.11
Fibonacci 50% 681.05
Fibonacci 38.2% 648.00
52-Week Low 541.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.